pirenzepine has been researched along with Acidosis, Diabetic in 11 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report the case of a patient taking olanzapine who developed diabetic ketoacidosis (DKA)." | 7.71 | Olanzapine-induced diabetic ketoacidosis. ( Ragucci, KR; Wells, BJ, 2001) |
| "Olanzapine has been associated with insulin resistance and new-onset diabetes mellitus." | 6.41 | Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. ( Doraiswamy, PM; McLendon, BM; Seaburg, HL, 2001) |
| "Olanzapine (Zyprexa) is an atypical neuroleptic used in adult and pediatric patients for the management of schizophrenia." | 5.31 | Diabetic ketoacidosis associated with olanzapine in an adolescent patient. ( Scott, SM; Selva, KA, 2001) |
| "To report the case of a patient taking olanzapine who developed diabetic ketoacidosis (DKA)." | 3.71 | Olanzapine-induced diabetic ketoacidosis. ( Ragucci, KR; Wells, BJ, 2001) |
| "Olanzapine has been associated with insulin resistance and new-onset diabetes mellitus." | 2.41 | Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. ( Doraiswamy, PM; McLendon, BM; Seaburg, HL, 2001) |
| "Olanzapine (Zyprexa) is an atypical neuroleptic used in adult and pediatric patients for the management of schizophrenia." | 1.31 | Diabetic ketoacidosis associated with olanzapine in an adolescent patient. ( Scott, SM; Selva, KA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kozian, R | 1 |
| Wilson, DR | 1 |
| D'Souza, L | 1 |
| Sarkar, N | 1 |
| Newton, M | 1 |
| Hammond, C | 1 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| Gatta, B | 1 |
| Rigalleau, V | 1 |
| Gin, H | 1 |
| Lindenmayer, JP | 1 |
| Patel, R | 1 |
| Von Hayek, D | 1 |
| Hüttl, V | 1 |
| Reiss, J | 1 |
| Schweiger, HD | 1 |
| Füessl, HS | 1 |
| Mir, S | 1 |
| Taylor, D | 1 |
| Selva, KA | 1 |
| Scott, SM | 1 |
| Seaburg, HL | 1 |
| McLendon, BM | 1 |
| Doraiswamy, PM | 1 |
| Johnson, RP | 1 |
| Al-Taher, MT | 1 |
| Madlock, LE | 1 |
| Guo, M | 1 |
| Nasdahl, CS | 1 |
| Ragucci, KR | 1 |
| Wells, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
2 reviews available for pirenzepine and Acidosis, Diabetic
| Article | Year |
|---|---|
Atypical antipsychotics and hyperglycaemia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dia | 2001 |
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Humans; Hyperglycemia; Ketone B | 2001 |
9 other studies available for pirenzepine and Acidosis, Diabetic
| Article | Year |
|---|---|
[Olanzapine-induced diabetes mellitus].
Topics: Adult; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Dose-Response | 2002 |
New-onset diabetes and ketoacidosis with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; D | 2003 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
Diabetic ketoacidosis with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; C-Peptide; Diabetic Ketoacidosis; Glycated Hemoglobin; | 1999 |
Olanzapine-induced ketoacidosis with diabetes mellitus.
Topics: Antipsychotic Agents; Antisocial Personality Disorder; Benzodiazepines; Diabetes Mellitus; Diabetic | 1999 |
[Hyperglycemia and ketoacidosis associated with olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Fatal Outcome; Female; Humans; | 1999 |
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Female; Hallucinations; Hu | 2001 |
Increasing insulin dose for olanzapine-related diabetes.
Topics: Benzodiazepines; Blood Glucose; Body Mass Index; Diabetic Ketoacidosis; Dose-Response Relationship, | 2002 |
Olanzapine-induced diabetic ketoacidosis.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Female; Humans; Middle Aged; Olanzapin | 2001 |